SAN DIEGO, CA, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a clinical-stage company developing medicines based on cannabinoid science, today announced that Dr. Jim DeMesa, CEO of EHP will be featured as a speaker at the International Cannabinoid-Derived Pharmaceuticals Summit to be held on December 11-12, 2018 at The Revere Hotel in Boston, MA. Details of the presentation are as follows:

Session: “ Designing Reliable Clinical Trials and Understanding the Patient Perspective”

Designing Reliable Clinical Trials and Understanding the Patient Perspective” Presentation Title: “ EHP-101: The Development Process Leading to Appropriate Clinical Trials for Cannabinoid New Chemical Entities”

EHP-101: The Development Process Leading to Appropriate Clinical Trials for Cannabinoid New Chemical Entities” Date and Time: Wednesday, December 12, 2018 at 1:15 PM EST

Wednesday, December 12, 2018 at 1:15 PM EST Location: The Revere Hotel, Boston, MA

The summit will discuss key issues ranging from the benchside to commercialization for cannabinoid drug developers. Speakers will discuss complex cannabinoid pharmacology, formulations, clinical trials, patient education and commercial challenges. The summit will also include roundtable sessions, panel discussions, and workshops to take a deep dive into formulation and commercial strategy challenges. For more information about this conference, please visit: www.international-cdp.com .

About Emerald Health Pharmaceuticals Inc.

Emerald Health Pharmaceuticals is developing product candidates derived from cannabinoids for the treatment of CNS, autoimmune, and other diseases. The Company has two families of new chemical entities, based on cannabidiol (CBD) and cannabigerol (CBG), that it has modified through rational drug design to affect validated receptors pertinent to targeted diseases. Its first drug candidate, EHP-101, is in Phase I clinical development for treating multiple sclerosis and scleroderma. Its second, EHP-102, is focused on treating Huntington’s disease and Parkinson’s disease. For more information, visit www.emeraldpharma.life or contact: info@emeraldpharma.life .

To the extent statements contained in this news release are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered "forward-looking statements," as described in the private securities litigation reform act of 1995, that reflect management's current beliefs and expectations. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "hope," "hypothesis," "intend," "may," "plan," "potential," "predict," "project," "should," "strategy," "will," "would," or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in these presentations include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) the anticipated timing of clinical data availability; (v) our ability to meet our milestones; and (vi) our expectations regarding our ability to obtain and maintain intellectual property protection. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals' investigational drug products have not been approved or cleared by the FDA.

For more information, visit www.emeraldpharma.life or contact: info@emeraldpharma.life